Staccato alprazolam
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stereotypical Prolonged Seizures
Conditions
Stereotypical Prolonged Seizures
Trial Timeline
Feb 3, 2022 → Nov 30, 2028
NCT ID
NCT05076617About Staccato alprazolam
Staccato alprazolam is a phase 3 stage product being developed by UCB for Stereotypical Prolonged Seizures. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05076617. Target conditions include Stereotypical Prolonged Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05076617 | Phase 3 | Recruiting |
| NCT05077904 | Phase 3 | Recruiting |
Competing Products
1 competing product in Stereotypical Prolonged Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Staccato alprazolam | UCB | Phase 3 | 74 |